ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.94
+0.16 (2.36%)
Dec 4, 2025, 4:00 PM EST - Market open
ImageneBio Stock Forecast
Stock Price Forecast
The 2 analysts that cover ImageneBio stock have a consensus rating of "Hold" and an average price target of $16, which forecasts a 130.55% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $30.
Price Target: $16 (+130.55%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for ImageneBio stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 1 |
| Hold | 0 | 0 |
| Sell | 0 | 1 |
| Strong Sell | 0 | 0 |
| Total | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Sell Initiates $2 | Sell | Initiates | $2 | -71.18% | Nov 25, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $30 | Buy | Initiates | $30 | +332.28% | Oct 24, 2025 |
Financial Forecast
Revenue This Year
269.34K
from 3.50M
Decreased by -92.30%
Revenue Next Year
n/a
from 269.34K
EPS This Year
-5.65
from -0.12
EPS Next Year
-3.23
from -5.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 840,000 | n/a | ||||
| Avg | 269,337 | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -76.0% | - | ||||
| Avg | -92.3% | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.94 | -2.12 | |||
| Avg | -5.65 | -3.23 | |||
| Low | -9.15 | -4.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.